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Objective: The aim of this study was to investigate the human leukocyte
antigen (HLA) class I (HLA‐A and HLA‐B) and II (HLA‐DRB1) allele and
haplotype frequencies in a group of Iranian patients with Buerger's disease
(BD) in comparison with a normal healthy control group.
Methods: A total of 70 unrelated male patients and 100 healthy controls from
Sina Hospital, Tehran, Iran, belonging to the same ethnic background, were
enrolled in this case‐control study. HLA‐A, B, and DRB1 typing were per-
formed by polymerase chain reaction with sequence‐specific primers
(PCR‐SSP).
Results: The results of this case‐control study showed that the frequency of
the HLA‐A*03:01 (odds ratio (OR) = 2.88, P value (Pv) = .002), HLA‐A*29:01
(OR = 15.31, Pv< .001), HLA‐DRB1*04:02 (OR = 3.41, Pv< .001), and HLA‐
DRB1*16:01 (OR = 8.16, Pv< .001) was significantly higher in BD patients
compared with healthy controls, whereas the frequency of the HLA‐
DRB1*01:01 (OR= 0.03, Pv< .001) was significantly lower in BD patients. The
most frequent extended haplotypes in our patients were HLA‐A*02:01‐B*55:01‐
DRB1*04:03.
Conclusion: This study is the first study evaluating an association between the
HLA pattern and BD in the patients with BD from North West and North Iran.
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sclerosis; Pc, corrected P value; PCR‐SSP, polymerase chain reaction with sequence‐specific primers; Pv, P values; RA, rheumatoid arthritis; T1D,
type 1 diabetes mellitus; TAO, thromboangiitis obliterans.
1 | INTRODUCTION
Thromboangiitis obliterans (TAO) or Buerger's disease
(BD) is a segmental occlusive inflammatory condition
of arteries and veins, characterized by thrombosis of
the affected vessels. It is a non‐atherosclerotic in-
flammatory disease affecting small and medium‐sized
arteries and veins of the upper and lower extremities.1
This disease occurs worldwide, but the highest in-
cidence of BD is reported in the Middle and the Far
East.2 The high incidence of BD in Japan, Sri Lanka
(formerly Ceylon), Indonesia, India, Iran, and Medi-
terranean countries including Turkey, has been re-
ported.3‐7 The prevalence of the disease among all
patients with peripheral arterial disease ranges from
values as low as 0.5% to 5.6% in Western Europe, to
values as high as 45% to 63% in India, and 16% to 66%
in Korea and Japan.8 Although the incidence of the
disease in Iran cannot be determined exactly due to the
lack of a nationwide epidemiological survey, it is
widely accepted on the basis of clinical experience that
Iran is one of the Middle Eastern countries in which
BD frequently occurs.3,9
The specific etiology of the disease remained unclear.
Secondary etiological factors which have a positive effect
on BD disease include age, sex, race, hereditary factor
(human leukocyte antigen (HLA) phenotype), auto-
immune process, occupation, blood changes (coagul-
ability, anticardiolipin antibodies, homocysteine), and
smoking.10,11 Epidemiological studies have indicated that
autoimmune mechanisms, such as the anti‐collagen types
I, III, and IV response12 and genetic factors may play a
significant role in disease pathogenesis.13
HLA allele and haplotype frequency analysis in BD
patients revealed an association with the Aw24(A*24),
Bw40(B*40), Bw54(B*54), Cw1(C*1), and DR2 antigens
and a low frequency of DR9 and DRw52 antigens com-
pared with those observed in normal unaffected Japanese
individuals.14 In a study by Chen et al,12 a positive as-
sociation with the DPB1*05:01 and DRB1*15:01 was re-
ported, and CD14 genotyping showed that the CD14 TT
genotype increased significantly in Japanese patients
with BD. Recently, Shapouri‐Moghaddam et al13 in-
vestigated four HLA‐A subtypes as well as 5 HLA‐B and
HLA‐DRB subtypes in patients with BD in Eastern
Iranian population in Mashhad, Iran.
As Sina and Imam University hospitals are the largest
referral centers in Iran and many patients with BD attend
the vascular surgery unit, the aim of the present case‐
control study was to investigate the HLA class I (A and B)
and II (DRB1) allele and haplotype frequencies in a group
of Iranian patients with BD and a normal healthy control
group.
2 | MATERIAL AND METHODS
2.1 | Study subjects
A total of 70 unrelated patients that had been diagnosed with
BD based on Shionoya's criteria15 who attended the vascular
surgery clinic of Sina Hospital affiliated with Tehran Uni-
versity of Medical Science, were randomly selected. Hundred
healthy controls were also randomly selected from blood
donors at Iranian blood transfusion organizations. Diagnosis
of BD was based on Shionoya's criteria,15 which included
history of smoking, disease onset before the age of 50, oc-
clusive lesions in the infrapopliteal artery, either upper limb
involvement or phlebitis migrans, and the absence of risk
factors for atherosclerosis except for smoking. None of the
controls had a family history of symptoms related to BD. The
patients and controls represented a heterogeneous ethnic
population from North West and North Iran, originating
from the states of Azerbaijan and Tehran.
2.2 | Ethical approval
This study protocol was approved by the local ethics
committee of the Tehran University of Medical Sciences.
The study protocol conformed to the ethical guidelines of
the 1975 Declaration of Helsinki as reflected by a priori
approval by the institution's Human Research Commit-
tee. Written informed consent was obtained from all
participants before the study.
2.3 | HLA typing
DNA was extracted from the 5‐mL venous blood samples
taken from each of the participants using a modified
salting‐out method. HLA‐A, B, and DRB1 typing was
performed by polymerase chain reaction with sequence‐
specific primers (PCR‐SSP), following Olerup and
Zetterquist's method.16 The HLA‐A, B, and DRB primers
were supplied by Heidelberg University (Heidelberg,
Germany). Polymerase chain reaction (PCR) reactions
were carried out in 10 μL volumes and amplification was
carried out in a Techne Genius thermal cyclers. Cycling
conditions included an initial denaturation step at 94°C
for 2 minutes, followed by 10 cycles of denaturation at
94°C for 10 seconds and annealing and extension at 65°C
for 60 seconds, then 20 cycles of denaturation at 94°C for
10 seconds, annealing at 61°C for 50 seconds and exten-
sion at 72°C for 30 seconds. After amplification, the PCR
products were electrophoresed on an agarose gel at 170 V
for 15minutes, and then DNA was visualized on an ultra‐
violet (UV) transilluminator.
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2.4 | Statistical analysis
Statistical analysis was performed using GraphPad
Prism version 5 (GraphPad Software Inc, 2010, La Jolla,
CA). Categorical outcomes were introduced as propor-
tions. A design‐based χ2 or Fisher's exact test were run
to assess the differences in the frequency and distribu-
tion of each allele. The odds ratio and its 95% confidence
intervals (CI) were calculated for the association of BD
with HLA‐A, B, and DRB alleles. For the multiple
analysis performed on each locus, P values (Pv) were
corrected for multiple comparisons and the corrected
P value (Pc) was calculated by dividing the P value by
the number of alleles in each locus using Bonferroni
correction.17 A corrected P value (Pc) of .05 or less was
considered to be significant.
3 | RESULTS
In this matched case‐control study, the patients were in
the age group of 22 to 65 years with a mean age of
39.8 years. All patients were male and heavy smokers,
with a history of smoking 12 to 38 cigarettes per day
(mean of 24 per day) for a period ranging between 8 and
30 years (mean 20 years).
The results of DNA typing analysis for the HLA‐A,
B, and DRB alleles of 70 Iranian patients with BD and the
control group are shown in Tables 1–3.
In the HLA‐A locus, the frequency of the A*03:01
(20% vs 8%, Pv= .002, Pc= significant) and A*29:01 (7.1%
vs 0.5%, Pv< .001, Pc= significant) was significantly
higher in patients compared with the healthy controls,
whereas the frequency of the A*11:01 and A*26:01 was
lower in patients (4.3% vs 13%, Pv= .044% and 2.9% vs
11%, Pv= .006, respectively) but did not reach statistical
significance after correction of the P value (Table 1).
In the HLA‐B locus, the frequency of the B*55:01
(8.6% vs 2.2%, Pv= .017), B*15:03 (2.9% vs 0%, Pv= .035),
and B*49:01 (4.3% vs 0.6%, Pv= 0.046) was increased in
patients compared with healthy controls but did not
reach statistical significance after correction of the
P value. The frequency of the B*57:01 (0% vs 4.4%,
Pv= 0.010) was decreased in the patient group compared
with the control group but this increase was not statis-
tically significant after correction of the P value (Table 2).
In the HLA‐DRB1 locus, the DRB1*04 and DRB1*16
were significantly increased (22.8% vs 8%, Pv< .001, Pc=
significant and 14.3% vs 2%, Pv< .001, Pc= significant,
respectively), whereas the DRB1*01:01 was significantly
reduced in patients compared with the healthy controls
(0.0% vs 9%, Pv< .001, Pc= significant) (Table 3).










ratio 95% CI P value Pc
01:01 14 (10.0%) 19 (9.5%) 1.06 0.51‐2.19 1 n.s.
02:01 26 (18.6%) 37 (18.5%) 1.00 0.58‐1.75 1 n.s.
03:01 28 (20.0%) 16 (8.0%) 2.88 1.49‐5.55 .002 Significant
11:01 6 (4.3%) 26 (13.0%) 0.3 0.12‐0.75 .045 n.s.
23:01 4 (2.9%) 8 (4.0%) 0.71 0.21‐2.39 .767 n.s.
24:02 10 (7.1%) 30 (15.0%) 0.44 0.20‐0.92 .027 n.s.
26:01 4 (2.9%) 22 (11.0%) 0.24 0.08‐0.71 .006 n.s.
29:01 10 (7.1%) 1 (0.5%) 15.31 1.94‐121.10 <.001 Significant
30:01 4 (2.9%) 8 (4.0%) 0.71 1.94‐121.10 .767 n.s.
31:01 2 (1.4%) 5 (2.5%) 0.57 0.11‐2.96 .704 n.s.
32:01 14 (10.0%) 11 (5.5%) 1.91 0.84‐4.34 .141 n.s.
33:01 6 (4.3%) 2 (1.0%) 4.43 0.88‐22.30 .069 n.s.
66:01 2 (1.4%) 0 (0.0%) 7.24a 0.34‐152 .169 n.s.
68:01 6 (4.3%) 12 (6.0%) 0.71 0.26‐1.92 .625 n.s.
68:02 0 (0.0%) 2 (1.0%) 0.28a 0.01‐5.93 .514 n.s.
69:01 4 (2.9%) 1 (0.5%) 5.85 0.65‐52.96 .164 n.s.
Abbreviations: BD, Buerger's disease; HLA, human leukocyte antigen; Pc, corrected P value; n.s., not significant.
aOdds ratio was calculated by adding 0.5 to each value.
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The frequency of the DRB1*08:01 and DRB1*13:02
(0% vs 4%, Pv= .023% and 0% vs 3%, Pv= .045, respec-
tively) were increased in the control group compared
with the patient group but this was not significant after
correction of the P value. The most frequent DRB1*04
subtype in our patients was the DRB1*04:02 (from 16
patients that were DRB1*04, 12 were DRB1*04:02, and 4
were DRB1*04:03).
4 | DISCUSSION
The extremely high levels of polymorphism and hetero-
zygosity within the major histocompatibility complex
(MHC) genomic region provide the immune system with
a selective advantage against the diversity and variability
of pathogens. However, the high rate of mutation within
MHC is accompanied by the added risk of generating
autoimmune diseases and other genetic disorders. Several
hundred autoimmune and infectious diseases have been
associated with the MHC genetic region, including type 1
diabetes mellitus (T1D), rheumatoid arthritis (RA),
multiple sclerosis (MS), and ankylosing spondylitis (AS),
however, the exact molecular mechanisms are un-
known.18 Like other autoimmune diseases, BD is a multi‐
factorial disease with predisposing genetic backgrounds
and environmental factors. The association between HLA
alleles and haplotypes and BD has been reported by










ratio 95% CI P value Pc
07:02 2 (1.4%) 4 (2.2%) 0.64 0.11‐3.53 .670 n.s.
07:03 0 (0.0%) 2 (1.1%) 0.25b 0.01‐5.34 .506 n.s.
07:05 3 (2.1%) 0 (0.0%) 9.18b 0.47‐179.50 .083 n.s.
08:01 4 (2.9%) 8 (4.4%) 0.56 0.19‐2.14 .561 n.s.
13:01 2 (1.4%) 8 (4.4%) 0.31 0.06‐1.49 .195 n.s.
14:02 2 (1.4%) 3 (1.7%) 0.86 0.14‐5.19 1 n.s.
15:01 6 (4.3%) 3 (1.7%) 2.64 0.65‐10.76 .187 n.s.
15:03 4 (2.9%) 0 (0.0%) 11.90b 0.63‐223.10 .036 n.s.
18:01 8 (5.7%) 6 (3.3%) 1.76 0.59‐5.19 .410 n.s.
35:01 18 (12.9%) 27 (15.0%) 0.84 0.44‐1.59 .629 n.s.
37:01 2 (1.4%) 5 (2.8%) 0.51 0.01‐2.655 .474 n.s.
38:01 8 (5.7%) 15 (8.3%) 0.67 0.27‐1.62 .393 n.s.
39:01 0 (0.0%) 4 (2.2%) 0.14b 0.01‐2.62 .134 n.s.
40:01 0 (0.0%) 2 (1.1%) 0.25b 0.01‐5.34 .506 n.s.
40:02 4 (2.9%) 2 (1.1%) 2.62 0.47‐14.51 .41 n.s.
41:01 6 (4.3%) 4 (2.2%) 1.97 0.54‐7.12 .343 n.s.
44:02 6 (4.3%) 5 (2.8%) 1.57 0.47‐5.25 .543 n.s.
44:03 10 (7.1%) 8 (4.4%) 1.65 0.63‐4.31 .334 n.s.
49:01 6 (4.3%) 1 (0.6%) 8.02 0.95‐67.40 .046 n.s.
50:01 6 (4.3%) 16 (8.9%) 0.46 0.17‐1.21 .123 n.s.
51:01 14 (10.0%) 29 (16.1%) 0.58 0.29‐1.14 .137 n.s.
52:01 12 (8.6%) 9 (5.0%) 1.78 0.73‐4.36 .256 n.s.
55:01 12 (8.6%) 4 (2.2%) 4.13 1.30‐13.09 .017 n.s.
57:01 0 (0.0%) 8 (4.4%) 0.07b 0.004‐1.26 .010 n.s.
Abbreviations: BD, Buerger's disease; HLA, human leukocyte antigen; Pc, corrected P value; n.s., not significant.
aFor HLA‐B locus, 90 healthy controls were randomly selected from blood donors at Iranian blood transfusion organizations that were enrolled in this study.
bOdds ratio was calculated by adding 0.5 to each value.
4 | DEHGHANI FIROUZABADI ET AL.
various investigators in different populations in endemic
regions.4,12,19‐21 Vijayakumar et al22 found that patients
diagnosed with BD have different forms in HLA haplo-
type and heterogeneity which is common between them.
Our study revealed the higher frequency of the A*03:01,
A*29:01, DRB1*04, and DRB1*16:01 and the lower the
frequency of the DRB1*01:01 in patients compared with
healthy controls.
HLA analysis of BD patients in India4 demonstrated a
positive association with the B40 and DR2 (DRB1*15:01,
*15:02, and *16:02). Although Iranian and some Indian
populations originate from Indo‐European Arian ancestors,
the frequency of the B*4001 and 4002 did not differ between
Iranian BD patients and healthy controls but the DR2,
specifically DRB1*16, increased significantly in Iranian pa-
tients with BD, similarly to Indian BD patients. These dif-
ferences in allele frequencies in Indian and Iranian
populations may be partially attributable to the typing
methodology, but also reflect ethnicity differences between
these populations.
HLA analysis of Japanese patients with BD12,19,23
revealed a positive association with the B*54:01,
DRB1*15:01, DRB1*04:05, and DPB1*05:01 and a
negative association with the DRB1*13:02 and
DRB1*04:01. Our findings in Iranian patients with BD
confirmed earlier reports on the association of BD with
DRB1*04 in Japanese patients. The most frequent
DRB1*04 subtypes in our patients were DRB1*04:02
and DRB1*04:03. Similarly, to the Japanese study, we
found that the frequency of the DRB1*13:02 was higher
in healthy controls compared with BD patients, but did
not reach statistical significance after correction of the P
value (3% vs 0%, Pv= 0.044). Other alleles were not
found to differ significantly in our population. A recent
study in an Eastern Iranian sample population,
Shapouri‐Moghaddam et al13 showed that the HLA‐
associated gene in patients with BD was associated with
four HLA‐A subtypes (ie, A*03, A*24, A*31, and A*11),
five HLA‐B subtypes (ie, B*27, B*15, B*07, B*51, and
B*44), and five HLA‐DRB1 subtypes (ie, DRB1*16,
DRB1*04, DRB1*14, DRB1*03, and DRB1*15). More-
over, they found that A*25, A*66, DRB1*08, DRB1*10,
and DRB1*12 was associated with an increased risk of
BD. Similar to that study, our study with larger sample
size of patients with BD from North West and North
Iran found that the frequencies of A*03, DRB1*04, and







ratio 95% CI P value PcN= 140 N= 200
01:01 0 (0.0%) 18 (9.0%) 0.03a 0.002‐0.59 <.001 Significant
03:01 14 (10.0%) 18 (9.0%) 1.12 0.54‐2.34 .851 n.s.
04 32 (22.9%) 16 (8.0%) 3.41 1.79‐6.50 <.001 Significant
07 10 (7.1%) 26 (13.0%) 0.51 0.24‐1.10 .107 n.s.
08:01 0 (0.00%) 8 (4.0%) 0.08a 0.004‐1.41 .023 n.s.
09:01 0 (0.00%) 2 (1.0%) 0.28a 0.01‐5.93 .514 n.s.
10:01 2 (1.4%) 6 (3.0%) 0.46 0.09‐2.36 .478 n.s.
11:01 27 (19.3%) 38 (19.0%) 1.02 0.59‐1.76 1 n.s.
11:02 2 (1.4%) 10 (5.0%) 0.27 0.06‐1.28 .132 n.s.
12 1 (0.7%) 0 (0.0%) 4.31a 0.17‐106.70 .412 n.s.
13:01 8 (5.7%) 12 (6.0%) 0.95 0.38‐2.39 1 n.s.
13:02 0 (0.0%) 6 (3.0%) 0.10a 0.01‐1.91 .045 n.s.
13:03 0 (0.0%) 2 (1.0%) 0.28a 0.01‐5.93 .514 n.s.
14:01 2 (1.4%) 8 (4.0%) 0.34 0.07‐1.66 .206 n.s.
15:01 22 (15.7%) 26 (13.0%) 1.24 0.67‐2.31 .528 n.s.
16:01 20 (14.3%) 4 (2.0%) 8.16 2.72‐24.47 <.001 Significant
Abbreviations: BD, Buerger's disease; HLA, human leukocyte antigen; Pc, corrected P value; n.s., not significant.
aOdds ratio was calculated by adding 0.5 to each value.
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DRB1*16 were increased in the patients. In contrast to
that study that showed HLA‐B*08, B*45, B*46, and B*53
had a protective role against BD, our study found that
DRB1*10:01 was decreased in the Buerger's patients.
Our findings also showed that A*02:01‐B*55:01‐
DRB1*04:03 was the most frequent extended haplotype
in the patients. The limitation of this study is its small
sample size, as these kind of studies require larger
sample sizes to achieve an adequate statistical power.
5 | CONCLUSION
In conclusion, our findings like other studies suggest that
a genetic marker in the HLA region along with some
environmental such as smoking and immunological fac-
tors may increase the risk of HLA‐associated suscept-
ibility genes in Buerger's patients. Further studies with a
larger sample size are needed to confirm these results and
establish the role of HLA alleles and haplotypes in BD
association.
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